Novartis is renowned for its commitment to: ? Innovative medicines – introducing new treatments annually.Continued prime position in cardiology and oncology – blockbuster products. Excellence in new product pipeline via research and development – one of the strongest in the industry with 145 products currently in development. Corporate responsibility in the UK and worldwide – in 2009, the Novartis access-to-medicines programmes, valued at USD 1.5billion, reached 79.5 million patients globally. Diversity and inclusion in employment.
Our mission at Novartis is to discover, develop and successfully market innovative products to prevent diseases, to ease suffering, and to enhance quality of life. We also want to provide a shareholder return that reflects outstanding performance and adequately rewards those who invest ideas into and work for our company. Novartis was created in 1996 from the merger of the Swiss based life sciences companies, Ciba-Geigy and Sandoz. At the time, the merger was the largest in corporate history. Since the merger in 1996, Novartis has transformed itself from a diverse group, including agribusiness, to a highly focused leading healthcare company.